Literature DB >> 17217403

Pharmacokinetics of a new long acting endectocide formulation containing 2.25% ivermectin and 1.25% abamectin in cattle.

F A Borges1, H S Cho, E Santos, G P Oliveira, A J Costa.   

Abstract

The objective of this study was to determine the kinetic parameters of a new formulation that contained 2.25% ivermectin combined with 1.25% abamectin in bovine plasma. The results for 2.25% ivermectin: Cmax (37.11 ng/mL +/- 7.42), Tmax (16 days +/- 5.29), T(1/2) (44.62 days +/- 53.89), AUC (928.2 ng x day/mL +/- 153.83) and MRT (36.73 days +/- 33.64), and for 1.25% abamectin: Cmax (28.70 ng/mL +/- 9.54), Tmax (14 days +/- 4.04), T(1/2) (15.40 days +/- 11.43), AUC (618.05 ng x day/mL +/- 80.27) and MRT (20.79 days +/- 8.43) suggest that this combination of 2.25% ivermectin + 1.25% abamectin possesses properties that give this pharmaceutical formula a longer activity time than two of the commercial products tested (1% ivermectin and 1% abamectin), and showed similarity to 3.15% ivermectin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17217403     DOI: 10.1111/j.1365-2885.2007.00816.x

Source DB:  PubMed          Journal:  J Vet Pharmacol Ther        ISSN: 0140-7783            Impact factor:   1.786


  2 in total

1.  Comparative pharmacokinetics of ivermectin alone and a novel formulation of ivermectin and rafoxanide in calves and sheep.

Authors:  H A El-Banna; A Goudah; H El-Zorba; S Abd-El-Rahman
Journal:  Parasitol Res       Date:  2008-02-23       Impact factor: 2.289

2.  Improved antifilarial activity of ivermectin in chitosan-alginate nanoparticles against human lymphatic filarial parasite, Brugia malayi.

Authors:  Mohammad Ali; Mohammad Afzal; Meenakshi Verma; Shailja Misra-Bhattacharya; Farhan Jalees Ahmad; Amit Kumar Dinda
Journal:  Parasitol Res       Date:  2013-07-05       Impact factor: 2.289

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.